Balkees Abderrahman is Postdoctoral Fellow, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.
Chemoprevention in British women is inadequateSubscription
We write to outline our concerns that breast cancer prevention strategies are not being implemented to their fullest potential in the UK. Breast cancer is the most common female cancer and the second leading cause of death in women in the UK. According to Cancer Research UK, there were more than 55,000 new cases of breast cancer and more than 11,000 deaths from breast cancer in 2014
Breast cancer prevention trumps cureSubscription
Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health. These medicines have been rigorously studied, and tens of thousands of women who at high risk of
Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) plus an aromatase inhibitor (AI), such as